JLE

Hépato-Gastro & Oncologie Digestive

MENU

Validated and promozing biomarkers in oesogastric cancers Volume 30, supplement 4, September 2023

Figures


  • Figure 1

  • Figure 2

  • Figure 3

Tables

Authors
1 CHU Jean Minjoz, Université de Franche Comté, Service d’anatomie pathologique, 25000 Besançon
2 CHU Jean Minjoz, Université de Franche Comté, Service de chirurgie, 25000 Besançon
3 CHU Jean Minjoz, Université de Franche Comté, Service d’oncologie, 25000 Besançon
4 CHU Jean Minjoz, Université de Franche Comté, Service d’oncobiologie génétique, 25000 Besançon
* Correspondance : F. Bibeau

Œsogastric cancers can now benefit from a personalized approach targeting the tumor and its microenvironment, mainly relying on tissue biomarkers determination. In the context of immunotherapy, TPS or CPS score assessment and MMR status are mandatory and EBV status might be useful. These parameters can lead to the use of immune check point inhibitors (anti-PD-1 and PD-L1) which recently revolutionized the therapeutic management of oesogastric cancers. Tumor targeting necessarily encompasses HER2 status which impact on trastuzumab use. In addition, other promising targets are available such as claudin 18, FGFR2 and NTRK, which might, for some of them, belong to the future clinical practice. The aim of this article is to describe the validated and promising oesogastric cancer biomarkers, and their assessment. We also highlight the importance of the management of the biopsy material in this era of precision medicine.